A Novel DMARD, Iguratimod Disrupts TGF-b Signaling in Epithelial Cells and Attenuates Bleomycin-Induced Interstitial Lung Disease in Mice

Qiong Luo,Xuelong Qian,Dongmei Hong,Yang Sun,Qiang Xu

DOI: https://doi.org/10.1254/jpssuppl.wcp2018.0_po4-5-25

2018-01-01

Proceedings for Annual Meeting of The Japanese Pharmacological Society

Abstract:Subsets of patients with rheumatoid arthritis (RA) always develop interstitial lung disease (ILD). In addition to environmental and genetic factors, lots of traditional disease-modifying antirheumatic drugs (DMARDs) for RA treatment have been reported to induce the fibrotic lung abnormalities. Here we show that iguratimod, a novel DMARD, dose-dependently and potently diminished the severity of bleomycin-induced lung fibrosis by attenuating TGF-b signaling, which is distinct from methotrexate. Mice were anaesthetized and then intratracheally injected with bleomycin at a dose of 5 U/kg body weight. For treatment, iguratimod was administered intragastrically (i.g.) at 10, 30, 100 mg/kg daily. Methotrexate was administered i.g. at 10 mg/kg every two days. Mice were monitored for body weight loss. On day 21 following bleomycin injection, mice were sacrificed and lungs were harvested for further analyses. We found that oral administration of iguratimod effectively diminished bleomycin-induced pulmonary inflammation. Further study showed that iguratimod protected alveolar epithelial cells from injury and reduced myofibroblast accumulation by attenuating TGF-b signaling. Furthermore, we found that, Act1, the target protein of iguratimod, was induced in response to TGF-b and in turn promoted TGF-b induced epithelial-mesenchymal transition. Increased Act1 expression has been found in lungs of bleomycin-induced fibrosis and also in the lungs of patients with IPF. Our data demonstrate an important role of Act1 in TGF-b signaling and pulmonary fibrosis, providing a novel approach for targeting Act1 in treating clinically refractory fibrotic diseases, such as RA-ILD.